MetaVia Inc. (NASDAQ:MTVA) shares are up during Friday’s premarket session as the company announced a strong global intellectual property portfolio supporting its lead asset, DA-1726.
MetaVia revealed that it has secured 39 granted and pending patents in the U.S. and internationally for DA-1726, which is designed for the treatment of obesity and related metabolic disorders. The patent protection extends into 2041, unless further extended, providing a solid foundation for the company’s long-term strategy.
The company's CEO, Hyung Heon Kim, emphasized the importance of this intellectual property estate, stating that it protects the unique design of DA-1726 as a dual GLP-1/glucagon agonist.
The recent clinical data showed promising results, with a 9% weight loss observed at the 48 mg dose, alongside significant improvements in waist size and blood sugar levels.
Technical Analysis
Currently, the stock is trading 21.8% below its 20-day simple moving average (SMA) and 77.6% below its 200-day SMA, indicating significant bearish pressure in the longer term. Over the past 12 months, shares have decreased by 90.85%, and they are positioned closer to their 52-week lows than highs.
The RSI is at 23.34, which is considered oversold territory, suggesting that the stock may be undervalued and could see a rebound. Meanwhile, the MACD is above the signal line, indicating a potential bullish momentum despite the overall bearish trend.
The combination of oversold RSI and bullish MACD suggests a potential for bullish momentum in the near term.
- Key Resistance: $2.00
- Key Support: $1.50
MetaVia is currently outperforming its sector, with a gain of approximately 10.2% compared to a 0.17% increase in the Healthcare sector. The Healthcare sector is ranked 5 out of 11 sectors, reflecting a mid-tier performance in the market.
Over the past 30 days, the sector has seen a slight decline of 1.18%, while it has gained 2.83% over the last 90 days. This context highlights that MetaVia’s current performance is a significant deviation from the sector’s recent trends.
Analyst Consensus & Recent Actions: The stock carries a Buy Rating. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Raises Target to $40.00) (Jan. 6)
MTVA Price Action: MetaVia shares were up 9.64% at $1.84 at the time of publication on Friday. The stock is trading near its 52-week low of $1.61, according to Benzinga Pro data.
Image via Shutterstock
